These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
929 related articles for article (PubMed ID: 34015317)
1. Azithromycin: Immunomodulatory and antiviral properties for SARS-CoV-2 infection. Khezri MR; Zolbanin NM; Ghasemnejad-Berenji M; Jafari R Eur J Pharmacol; 2021 Aug; 905():174191. PubMed ID: 34015317 [TBL] [Abstract][Full Text] [Related]
2. Azithromycin in the treatment of COVID-19: a review. Echeverría-Esnal D; Martin-Ontiyuelo C; Navarrete-Rouco ME; De-Antonio Cuscó M; Ferrández O; Horcajada JP; Grau S Expert Rev Anti Infect Ther; 2021 Feb; 19(2):147-163. PubMed ID: 32853038 [TBL] [Abstract][Full Text] [Related]
3. Antiviral effects of azithromycin: A narrative review. Khoshnood S; Shirani M; Dalir A; Moradi M; Haddadi MH; Sadeghifard N; Birjandi FS; Yashmi I; Heidary M Biomed Pharmacother; 2022 Mar; 147():112682. PubMed ID: 35131658 [TBL] [Abstract][Full Text] [Related]
4. Can endolysosomal deacidification and inhibition of autophagy prevent severe COVID-19? Morris G; Athan E; Walder K; Bortolasci CC; O'Neil A; Marx W; Berk M; Carvalho AF; Maes M; Puri BK Life Sci; 2020 Dec; 262():118541. PubMed ID: 33035581 [TBL] [Abstract][Full Text] [Related]
5. A short focus, azithromycin in the treatment of respiratory viral infection COVID-19: efficacy or inefficacy? Vitiello A; Ferrara F Immunol Res; 2022 Feb; 70(1):129-133. PubMed ID: 34739696 [TBL] [Abstract][Full Text] [Related]
7. Direct inhibitory effect on viral entry of influenza A and SARS-CoV-2 viruses by azithromycin. Du X; Zuo X; Meng F; Han C; Ouyang W; Han Y; Gu Y; Zhao X; Xu F; Qin FX Cell Prolif; 2021 Jan; 54(1):e12953. PubMed ID: 33211371 [TBL] [Abstract][Full Text] [Related]
8. In silico study of azithromycin, chloroquine and hydroxychloroquine and their potential mechanisms of action against SARS-CoV-2 infection. Braz HLB; Silveira JAM; Marinho AD; de Moraes MEA; Moraes Filho MO; Monteiro HSA; Jorge RJB Int J Antimicrob Agents; 2020 Sep; 56(3):106119. PubMed ID: 32738306 [TBL] [Abstract][Full Text] [Related]
9. Immunomodulatory agents as potential therapeutic or preventive strategies for COVID-19. Gaziano R; Pistoia ES; Campione E; Fontana C; Marino D; Favaro M; Pica F; Di Francesco P Eur Rev Med Pharmacol Sci; 2021 Jun; 25(11):4174-4184. PubMed ID: 34156699 [TBL] [Abstract][Full Text] [Related]
10. Synergistic antiviral effect of hydroxychloroquine and azithromycin in combination against SARS-CoV-2: What molecular dynamics studies of virus-host interactions reveal. Fantini J; Chahinian H; Yahi N Int J Antimicrob Agents; 2020 Aug; 56(2):106020. PubMed ID: 32862840 [TBL] [Abstract][Full Text] [Related]
11. Effectiveness of Azithromycin as Add-on Therapy in COVID-19 Management. Wahab S; Ahmad MF; Hussain A; Usmani S; Shoaib A; Ahmad W Mini Rev Med Chem; 2021; 21(19):2860-2873. PubMed ID: 33797374 [TBL] [Abstract][Full Text] [Related]
12. COVID-19 and chronological aging: senolytics and other anti-aging drugs for the treatment or prevention of corona virus infection? Sargiacomo C; Sotgia F; Lisanti MP Aging (Albany NY); 2020 Mar; 12(8):6511-6517. PubMed ID: 32229706 [TBL] [Abstract][Full Text] [Related]
13. Old and re-purposed drugs for the treatment of COVID-19. Jean SS; Hsueh PR Expert Rev Anti Infect Ther; 2020 Sep; 18(9):843-847. PubMed ID: 32419524 [No Abstract] [Full Text] [Related]
14. Cysteamine with In Vitro Antiviral Activity and Immunomodulatory Effects Has the Potential to Be a Repurposing Drug Candidate for COVID-19 Therapy. Alonzi T; Aiello A; Petrone L; Najafi Fard S; D'Eletto M; Falasca L; Nardacci R; Rossin F; Delogu G; Castilletti C; Capobianchi MR; Ippolito G; Piacentini M; Goletti D Cells; 2021 Dec; 11(1):. PubMed ID: 35011614 [TBL] [Abstract][Full Text] [Related]
15. Nitazoxanide and COVID-19: A review. Al-Kuraishy HM; Al-Gareeb AI; Elekhnawy E; Batiha GE Mol Biol Rep; 2022 Nov; 49(11):11169-11176. PubMed ID: 36094778 [TBL] [Abstract][Full Text] [Related]
17. Proactive Prophylaxis With Azithromycin and HydroxyChloroquine in Hospitalised Patients With COVID-19 (ProPAC-COVID): A structured summary of a study protocol for a randomised controlled trial. Sivapalan P; Ulrik CS; Bojesen RD; Lapperre TS; Eklöf JV; Håkansson KEJ; Browatzki A; Tidemansen C; Wilcke JT; Janner J; Gottlieb V; Meteran H; Porsbjerg C; Madsen BL; Moberg M; Pedersen L; Benfield TL; Lundgren JD; Knop FK; Biering-Sørensen T; Ghanizada M; Sonne TP; Bødtger UCS; Jensen SG; Rasmussen DB; Brøndum E; Tupper OD; Sørensen SW; Alstrup G; Laursen CB; Møller UW; Sverrild A; Jensen JS Trials; 2020 Jun; 21(1):513. PubMed ID: 32522282 [TBL] [Abstract][Full Text] [Related]
18. Diverse effects of clarithromycin and proposal of its clinical application for treating COVID-19 as a repurposing drug. Takemori N; Ooi HK; Imai G; Saio M Trop Biomed; 2021 Sep; 38(3):343-352. PubMed ID: 34508342 [TBL] [Abstract][Full Text] [Related]
19. COVID-19 and L-arginine Supplementations: Yet to Find the Missed Key. Al-Kuraishy HM; Al-Gareeb AI; Alexiou A; Batiha GE Curr Protein Pept Sci; 2022; 23(3):166-169. PubMed ID: 35549865 [TBL] [Abstract][Full Text] [Related]
20. Are clarithromycin, azithromycin and their analogues effective in the treatment of COVID19? Gedikli MA; Tuzun B; Aktas A; Sayin K; Ataseven H Bratisl Lek Listy; 2021; 122(2):101-110. PubMed ID: 33502877 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]